Epidemics of influenza A have been associated with excess mortality and morbidity in compromised hosts and the elderly (3). Recently, acute rejection of transplanted kidneys during influenza A outbreaks has been reported (1) , indicating that transplant recipients may fall into the "high-risk" group. It follows that they may benefit from the protection provided by influenza vaccine. The following study was designed to assess both the homologous and heterologous humoral antibody response to influenza vaccine in a group ofrenal transplant patients.
MATERIALS AND METHODS Study population. The study population consisted of two groups: (i) a group of 45 renal transplant recipients cared for under the University of Colorado transplant program, and (ii), a control group of 66 freshman medical students enrolled at the University of Colorado Medical School. The transplant patients were receiving immunosuppressive drugs, usually prednisone and azathoprine (four patients were receiving prednisone plus cyclophosphamide).
None of the control population were receiving immunosuppressive drugs. The mean age of the transplant group was 28 years (range, 6 to 46 years), and the mean age of the control group was 23 years (range, 21 to 38 years).
HL-A tissue typing had been performed previously on the transplant patients. Tests were performed by Yosh Arai in the Research Laboratories, Veterans Administration Hospital, Denver, Colo., by the microdroplet lymphocyte cytotoxicity test (7) with tissue-typing plates supplied by P. I. Terasaki, UCLA School of Medicine, and by the National Institutes of Health, Bethesda, Md. Tissue types were analyzed in retrospect, and results were available for only 30 ofthe 45 transplant patients who received influenza vaccine.
Vaccination procedures. In October and November 1972, each individual in the study groups received 0.5 ml of bivalent ether-split aqueous inactivated influenza vaccine (Fluogen, Parke, Davis Co.) containing 700 chicken cell-agglutinating units ofA/ Aichi/2/68/X-31 (H3N2) and 300 chicken cell-agglutinating units of B/Massachusetts/1/71 antigen intramuscularly. Twelve transplant patients had received influenza vaccine within the previous 3 years. None of the controls had received influenza vaccine before. Before vaccination and from 4 to 6 weeks after, blood samples were drawn and the paired sera were tested to determine the antibody response.
Determination of antibody response. Paired sera were tested by the hemagglutination inhibition test with chicken erythrocytes, using the microtiter method with microtiter and macrotiter virus controls (10 
RESULTS
There was no difference in prevaccination seronegativity rates (titers -8) between those with fourfold vaccine response and those without, comparing the student group and transplant group, for any of the virus strains tested.
The antibody response to the homologous influenza A strain is illustrated in Fig. 1 . The diagonal lines in the figure represent, from top to bottom, fourfold, twofold, and no rise in antibody titer. Only 14 of 45 transplant patients (31%) demonstrated a fourfold or greater titer rise, compared with a significantly higher rate, 37 out of 66 (56%), in the control group (P = 0.01). Twenty-two transplant recipients showed no rise at all compared with 13 controls. When the response to a heterologous virus, A/Denver/ 1/72 (H3N2), was examined, there was an even poorer response rate in the transplant recipients (Fig. 2) . A fourfold or greater titer rise was found in 40 of 66 controls (61%), but only in 8 of 45 transplant patients (18%) (P < 0.001). No rise was detected in 35 transplant patients and in 20 of the control group.
The antibody responses to vaccination with B/Massachusetts/1/71 against the homologous B strain is illustrated in Fig. 3 The association of immune response and HL-A type has been studied previously. Spencer et al. showed that type W16 was associated with a decreased antibody response to A/England/42/ 72 (H3N2) in normal subjects vaccinated with live "Alice" strain vaccine but not with inactivated vaccine (11) . Our data on the increased antibody response in transplant patients with W15 as compared with those with other HL-A types are interesting but difficult to interpret since no HL-A typing was performed on the control group.
These data demonstrate that as a group, renal transplant patients have an impaired antibody response to inactivated influenza vaccine when compared with young healthy individuals. Double-dose vaccination or some type of adjuvant vaccination should be studied in this group to see if a more optimal antibody response rate can be achieved.
